



MEN

FIRST CANCER SITE BLADDER AND URINARY TRACT

BLADDER AND URINARY TRACT POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

VESCICA E VIE URINARIE POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	89641		95005		95005		89641		73015		34454		12760		89641	95005
Person-years ▶	431215		446601		15386		67213		203505		111154		49343		431215	446601
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT BLADDER AND URINARY TRACT	11281	1.28	12517	1.38	1236	4.20	2072	1.62	4833	1.21	2933	1.25	1443	1.27	5.79	7.70
HEAD AND NECK	537	1.43	554	1.42	17	1.26	88	1.50	253	1.42	137	1.42	59	1.39	0.37	0.37
ORAL CAVITY	110	1.26	114	1.26	4	1.30	17	1.27	53	1.30	27	1.19	13	1.28	0.05	0.05
PHARYNX	94	1.24	98	1.25	4	1.47	16	1.35	49	1.36	20	1.03	9	1.06	0.04	0.04
LARYNX	333	1.57	342	1.55	9	1.17	55	1.64	151	1.50	90	1.65	37	1.55	0.28	0.27
OESOPHAGUS	115	1.15	122	1.18	7	2.01	17	1.13	49	1.06	38	1.46	11	0.90	0.04	0.04
STOMACH	578	0.94	598	0.94	20	0.93	71	0.77	266	0.94	168	1.04	73	0.96	-0.08	-0.09
COLON RECTUM	1416	1.04	1476	1.05	60	1.33	194	0.99	618	1.00	388	1.05	216	1.19	0.12	0.15
COLON	988	1.05	1028	1.06	40	1.30	124	0.93	449	1.06	263	1.03	152	1.20	0.11	0.13
RECTUM	428	1.01	448	1.02	20	1.39	70	1.12	169	0.87	125	1.10	64	1.18	0.01	0.02
LIVER	424	1.08	442	1.09	18	1.34	56	0.96	185	1.02	126	1.21	57	1.14	0.07	0.08
GALLBLADDER	104	0.94	108	0.95	4	1.08	23	1.43	48	0.96	24	0.81	9	0.62	-0.01	-0.01
PANCREAS	306	1.14	318	1.15	12	1.34	46	1.19	144	1.19	72	1.00	44	1.24	0.09	0.09
LUNG	3147	1.82	3487	1.95	340	5.70	378	1.46	1407	1.76	920	2.02	442	2.06	3.29	3.80
SKIN MELANOMA	145	1.14	157	1.19	12	2.96	17	0.95	69	1.20	40	1.15	19	1.08	0.04	0.06
MESOTHELIOMA	49	0.99	53	1.03	4	2.51	4	0.57	24	1.07	13	0.96	8	1.19	0.00	0.00
KAPOSI SARCOMA	13	0.62	14	0.65	1	1.37	1	0.32	8	0.83	3	0.55	1	0.38	-0.02	-0.02
SOFT TISSUE	43	1.31	43	1.26	0	0.00	8	1.67	14	0.93	12	1.36	9	2.09	0.02	0.02
BONE	13	1.53	13	1.48	0	0.00	1	0.75	7	1.76	4	1.83	1	1.01	0.01	0.01
BREAST	26	1.25	27	1.25	1	1.43	4	1.32	15	1.57	7	1.25	0	0.00	0.01	0.01
PROSTATE	2703	1.39	3314	1.65	611	9.84	889	3.27	1011	1.16	533	0.99	270	1.01	1.75	2.92
TESTIS	12	1.38	17	1.89	5	15.77	2	1.44	7	1.69	2	0.91	1	1.06	0.01	0.02
KIDNEY AND RENAL PELVIS	371	1.26	427	1.40	56	5.77	109	2.56	114	0.85	95	1.20	53	1.38	0.18	0.28
BLADDER AND URINARY TRACT	135	0.12	178	0.15	43	1.13	37	0.22	57	0.11	26	0.09	15	0.10	-2.28	-2.19
URINARY BLADDER	83	0.08	115	0.10	32	0.88	31	0.20	37	0.08	8	0.03	7	0.05	-2.29	-2.22
URINARY TRACT	52	1.08	63	1.26	11	6.87	6	0.86	20	0.92	18	1.38	8	1.24	0.01	0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	85	0.80	87	0.79	2	0.54	9	0.56	35	0.71	30	1.07	11	0.84	-0.05	-0.05
THYROID	41	1.06	42	1.05	1	0.78	1	0.18	21	1.18	9	0.87	10	2.08	0.01	0.00
HODGKIN LYMPHOMA	18	1.04	19	1.06	1	1.59	0	0.00	11	1.34	5	1.12	2	1.00	0.00	0.00
NON-HODGKIN LYMPHOMA	263	0.97	274	0.98	11	1.22	30	0.76	135	1.09	63	0.87	35	1.00	-0.02	-0.01
MYELOMA	138	1.05	144	1.06	6	1.36	19	0.99	63	1.06	37	1.05	19	1.11	0.02	0.02
LEUKAEMIAS	265	1.16	272	1.15	7	0.89	36	1.06	125	1.20	75	1.24	29	1.00	0.09	0.08
LYMPHOID LEUKAEMIAS	102	0.94	107	0.96	5	1.33	12	0.74	52	1.04	26	0.91	12	0.89	-0.01	-0.01
MYELOID LEUKAEMIAS	147	1.43	148	1.39	1	0.29	23	1.53	67	1.44	42	1.52	15	1.11	0.10	0.09
OTHER LEUKAEMIAS	16	0.94	17	0.96	1	1.61	1	0.38	6	0.76	7	1.58	2	0.98	0.00	0.00
OTHER AND ILL DEFINED SITES	469	0.90	509	0.94	40	2.27	69	0.90	204	0.86	132	0.94	64	0.92	-0.13	-0.07

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE BLADDER AND URINARY TRACT

BLADDER AND URINARY TRACT POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

VESCICA E VIE URINARIE POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	22375	24068		24068		22375		17595		8675		3362		22375	24068
Person-years ▶	107708	111573		3865		16453		49365		28631		13259		107708	111573	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT BLADDER AND URINARY TRACT	1585	1.21	1749	1.29	164	3.55	228	1.18	696	1.18	430	1.20	231	1.32	2.51	3.48
HEAD AND NECK	27	1.60	27	1.55	0	0.00	4	1.61	15	1.98	5	1.09	3	1.35	0.09	0.09
ORAL CAVITY	9	0.95	9	0.92	0	0.00	1	0.73	4	0.95	2	0.77	2	1.54	0.00	-0.01
PHARYNX	8	2.36	8	2.28	0	0.00	1	1.94	5	3.21	1	1.11	1	2.40	0.04	0.04
LARYNX	10	2.51	10	2.42	0	0.00	2	3.34	6	3.31	2	1.88	0	0.00	0.06	0.05
OESOPHAGUS	13	1.82	13	1.76	0	0.00	1	0.95	7	2.21	2	1.03	3	3.09	0.05	0.05
STOMACH	80	0.89	81	0.87	1	0.30	12	0.88	39	0.97	21	0.87	8	0.69	-0.09	-0.11
COLON RECTUM	216	0.97	229	0.99	13	1.67	35	1.08	93	0.94	54	0.89	34	1.12	-0.06	-0.01
COLON	165	1.03	176	1.06	11	1.96	24	1.03	79	1.11	42	0.95	20	0.90	0.04	0.09
RECTUM	51	0.83	53	0.83	2	0.91	11	1.20	14	0.51	12	0.72	14	1.72	-0.10	-0.10
LIVER	43	1.09	45	1.10	2	1.44	2	0.34	20	1.14	13	1.20	8	1.49	0.03	0.04
GALLBLADDER	27	0.84	28	0.84	1	0.86	3	0.63	13	0.91	7	0.81	4	0.94	-0.05	-0.05
PANCREAS	83	1.38	85	1.37	2	0.97	12	1.40	35	1.34	17	1.02	19	2.21	0.21	0.21
LUNG	242	2.76	284	3.13	42	14.22	29	2.32	107	2.77	69	2.84	37	3.01	1.43	1.73
SKIN MELANOMA	25	1.10	28	1.20	3	3.90	0	0.00	11	1.09	11	1.77	3	0.98	0.02	0.04
MESOTHELIOMA	4	1.12	4	1.08	0	0.00	0	0.00	1	0.63	2	2.01	1	1.97	0.00	0.00
KAPOSI SARCOMA	3	1.46	3	1.41	0	0.00	1	3.30	0	0.00	1	1.79	1	3.56	0.01	0.01
SOFT TISSUE	13	2.35	16	2.80	3	15.77	2	2.49	7	2.85	2	1.32	2	2.67	0.07	0.09
BONE	3	2.00	3	1.93	0	0.00	1	4.34	1	1.48	1	2.48	0	0.00	0.01	0.01
BREAST	363	1.15	388	1.19	25	2.27	42	0.89	158	1.11	105	1.23	58	1.43	0.44	0.55
CERVIX UTERI	24	1.51	42	2.55	18	29.97	7	2.76	10	1.35	6	1.46	1	0.55	0.08	0.23
CORPUS UTERI	56	0.98	83	1.41	27	13.39	11	1.27	22	0.84	18	1.18	5	0.71	-0.01	0.21
OVARY	43	1.06	45	1.07	2	1.39	5	0.82	23	1.25	10	0.91	5	0.96	0.02	0.03
KIDNEY AND RENAL PELVIS	49	1.49	57	1.68	8	7.23	10	2.13	21	1.44	9	0.99	9	1.98	0.15	0.21
BLADDER AND URINARY TRACT	26	0.47	42	0.74	16	8.33	11	1.37	6	0.25	7	0.46	2	0.26	-0.27	-0.13
URINARY BLADDER	19	0.37	34	0.64	15	8.42	11	1.48	4	0.18	3	0.21	1	0.14	-0.30	-0.17
URINARY TRACT	7	1.74	8	1.92	1	7.20	0	0.00	2	1.14	4	3.60	1	1.73	0.03	0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	19	0.99	20	1.00	1	1.51	3	1.06	7	0.81	8	1.52	1	0.39	0.00	0.00
THYROID	25	1.30	26	1.31	1	1.54	3	1.06	17	1.95	3	0.58	2	0.82	0.05	0.06
HODGKIN LYMPHOMA	5	1.73	5	1.66	0	0.00	1	2.21	2	1.49	2	2.64	0	0.00	0.02	0.02
NON-HODGKIN LYMPHOMA	54	1.07	57	1.09	3	1.71	6	0.81	18	0.79	17	1.23	13	1.92	0.03	0.04
MYELOMA	21	0.85	23	0.90	2	2.30	5	1.37	10	0.91	5	0.74	1	0.30	-0.03	-0.02
LEUKAEMIAS	32	0.90	32	0.87	0	0.00	5	0.95	12	0.76	13	1.34	2	0.42	-0.03	-0.04
LYMPHOID LEUKAEMIAS	10	0.63	10	0.61	0	0.00	3	1.26	3	0.42	3	0.71	1	0.49	-0.05	-0.06
MYELOID LEUKAEMIAS	20	1.20	20	1.16	0	0.00	2	0.83	8	1.09	9	1.97	1	0.44	0.03	0.03
OTHER LEUKAEMIAS	2	0.61	2	0.59	0	0.00	0	0.00	1	0.69	1	1.11	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	115	1.05	125	1.10	10	2.58	28	1.75	47	0.98	29	0.96	11	0.71	0.05	0.10

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio